1 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 25, 1997 GENELABS TECHNOLOGIES, INC. (Exact Name of Registrant as Specified in Charter) California 0-19222 94-3010150 (State or Other Jurisdiction (Commission File No.) (IRS Employer of Incorporation) Identification No.) 505 Penobscot Drive Redwood City, CA 94063 (Address of Principal Executive Offices) Registrant's telephone number, including area code: (415) 369-9500 2 Item 5. Other Events Genelabs Technologies, Inc. (the "Company") recently announced preliminary results of its first Phase III trial of GL701 for lupus. A copy of the press release announcing these results is attached hereto as Exhibit 99.1 and incorporated by reference herein. See the information appearing under the caption "Risk Factors" in the Company's report on Form 10-K for the year ended December 31, 1996 for certain information about risks associated with clinical trials, the Company's early stage development, the lack of assurance of regulatory approvals and other risks which may affect the Company. Item 7. Financial Statements and Exhibits (c) Exhibits EXHIBIT NUMBER DESCRIPTION 99.1 Press Release, dated April 25, 1997. 2. 3 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Genelabs Technologies, Inc. Dated: April 25, 1997 By: /S/ Irene A. Chow -------------------------- Irene A. Chow President and Chief Executive Officer 3. 4 INDEX TO FINANCIAL STATEMENTS AND EXHIBITS EXHIBIT NUMBER DESCRIPTION 99.1 Press Release, dated April 25, 1997 4.